Current status of renal transplantation--1986.
During the course of 3 decades, and particularly during the past 5 years, clinical renal transplantation has improved to become a safe mode of therapy for end-stage renal disease. Currently, more than 95% 1-year survival can be expected, both in patients who receive allografts from living-related donors and in those who receive cadaver kidneys. One-year living-related donor graft survival is 98%, and 1-year cadaver graft survival is 87%. Cyclosporine has been an important adjunctive immunosuppressive agent not only because of improved results but also because it has shortened hospitalization time.
D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002102:Cadaver; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000187:drug effects; D006680:HLA Antigens / Q000032:analysis; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007668:Kidney / Q000276:immunology; D007676:Kidney Failure, Chronic / Q000601:surgery; D016030:Kidney Transplantation; D008875:Middle Aged; D012086:Reoperation; D014019:Tissue Donors
D000961:Antilymphocyte Serum; D006680:HLA Antigens; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II; D007166:Immunosuppressive Agents